HEMORRHAGIC SHOCK TREATMENT MARKET ANALYSIS
Global Hemorrhagic Shock Treatment Market: Key Developments
For instance, on March 20, 2023, Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced two key publications. These publications add to the understanding of adrenergic receptors in the treatment of shock.Controls of central and peripheral blood pressure are critical in treating patients with hemorrhagic/hypovolemic shock. It has been demonstrated that alpha2-adrenergic receptors could be a suitable target for managing hypovolemic shock.
On May 14, 2020, Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced that it has received marketing authorization for centhaquine, a first-in-class drug, to manage patients with hypovolemic shock from the Indian regulatory agency. Centhaquine is likely to be a transformational therapy for hypovolemic shock because it ameliorates key drivers of mortality.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :